Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | NPC1 | O15118 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9571856 | 0.96 | SMN1; SMN2 (0.87) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL29854660 | 0.92 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL205216 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Hydrochloric Acid SCHEMBL3097843 | 0.87 | SMN1; SMN2 (0.97) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2662865 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL19682978 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2712105 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1939902 | 0.86 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2320849 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL14992459 | 0.85 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0542671-A1 | Substituted hydroquinone derivatives as intermediates of benzofuran derivatives | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | claimed |
| EP-0302788-B1 | 2-[Methyl(4-piperidinyl)]-1,2,3,4-tetrahydro-9H-pyrido[3,4-b] indole derivatives, their preparation and therapeutical use | SYNTHELABO (FR) | 1992-02-05 | — | — | EP | claimed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2024-12-24 | — | — | US | disclosed |
| US-20240336612-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-10-10 | — | — | US | disclosed |
| US-20240158374-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2024-05-16 | — | — | US | disclosed |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-04-18 | — | — | US | disclosed |
| WO-2024030000-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-02-08 | — | — | WO | disclosed |
| US-6218410-B1 | ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1058680-A1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-13 | — | — | EP | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
| WO-1999043657-A1 | 2-ARYLETHYL-(PIPERIDIN-4-YLMETHYL)AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-02 | — | — | WO | disclosed |
| US-5693807-A | Substituted hydroquinone derivatives | CIBA-GEIGY CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| US-5290939-A | Process for the manufacture of brofaromine and analogs thereof | CIBA-GEIGY CORPORATION (US) | 1994-03-01 | — | — | US | disclosed |
| US-5057504-A | PESTICIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-10-15 | — | — | US | disclosed |
| EP-0243184-A2 | Pesticidal compounds | ROUSSEL-UCLAF (FR) | 1987-10-28 | — | — | EP | disclosed |
| US-4243666-A | HYPOTENSIVE AGENTS | PFIZER INC. (US) | 1981-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172984-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SMN1; SMN2 564/4885NPC1 4529/4885RAB9A 2816/4885 |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | SMN1; SMN2 564/4885NPC1 4529/4885RAB9A 2816/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | SMN1; SMN2 564/4885NPC1 4529/4885RAB9A 2816/4885 |
| US-20240336612-A1 | BRM Targeting Compounds And Associated Methods Of Use | ADRM1, BRDT, RBX1 | SMN1; SMN2 2559/4885NPC1 1595/4885RAB9A 1873/4885 |
| US-20240124467-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | SMN1; SMN2 2230/4885NPC1 4188/4885RAB9A 2861/4885 |
| US-20240158374-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | SMN1; SMN2 564/4885NPC1 4529/4885RAB9A 2816/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | SMN1; SMN2 564/4885NPC1 4529/4885RAB9A 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.